Literature DB >> 8170175

Incidence of chronic lymphocytic leukemia in Olmsted County, Minnesota, 1935 through 1989, with emphasis on changes in initial stage at diagnosis.

T G Call1, R L Phyliky, P Noël, T M Habermann, C M Beard, W M O'Fallon, L T Kurland.   

Abstract

OBJECTIVE: To determine whether the stage at the time of diagnosis of chronic lymphocytic leukemia (CLL) had changed during a 55-year period.
DESIGN: We conducted a study of the cohort of residents of Olmsted County, Minnesota, who had been diagnosed as having CLL during the period from 1935 through 1989.
MATERIAL AND METHODS: By analysis of medical records, patients with CLL were characterized by Rai stage, absolute lymphocyte count, age at diagnosis, need for therapy, and reported cause of death in nonsurvivors. Trends for these variables were analyzed by decade throughout the study period.
RESULTS: The overall annual incidence rate of CLL per 100,000 population in Olmsted County increased from 2.6 in the 1935 through 1944 period to 5.4 in the 1975 through 1984 period; however, the increasing rate was found only for those 50 years of age or older and was especially dramatic for those 75 years old or older. Analysis of Rai stage over time demonstrated an increase in the proportion of cases diagnosed as Rai stage 0. In addition, the median absolute lymphocyte count decreased, the median time to initiation of therapy increased, and the median age of patients with Rai stage 0 CLL at the time of diagnosis increased over time. Overall, 54% of patients had received therapy for CLL by the time of last follow-up. Among the nonsurvivors, CLL was documented as the underlying or a contributing cause of death in 69%.
CONCLUSION: The overall increase in CLL was thought to be due to enhanced methods of early diagnosis and improved health care for the elderly population. Thus, artifact may best explain the observed trend, although we cannot exclude the possibility of an actual increase in incidence rates over time.

Entities:  

Mesh:

Year:  1994        PMID: 8170175     DOI: 10.1016/s0025-6196(12)62215-0

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  23 in total

1.  Highly skewed X-chromosome inactivation is associated with idiopathic recurrent spontaneous abortion.

Authors:  M C Lanasa; W A Hogge; C Kubik; J Blancato; E P Hoffman
Journal:  Am J Hum Genet       Date:  1999-07       Impact factor: 11.025

2.  Deep sequencing identifies genetic heterogeneity and recurrent convergent evolution in chronic lymphocytic leukemia.

Authors:  Juhi Ojha; Jackline Ayres; Charla Secreto; Renee Tschumper; Kari Rabe; Daniel Van Dyke; Susan Slager; Tait Shanafelt; Rafael Fonseca; Neil E Kay; Esteban Braggio
Journal:  Blood       Date:  2014-11-06       Impact factor: 22.113

3.  Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia.

Authors:  Muller Fabbri; Arianna Bottoni; Masayoshi Shimizu; Riccardo Spizzo; Milena S Nicoloso; Simona Rossi; Elisa Barbarotto; Amelia Cimmino; Brett Adair; Sylwia E Wojcik; Nicola Valeri; Federica Calore; Deepa Sampath; Francesca Fanini; Ivan Vannini; Gerardo Musuraca; Marie Dell'Aquila; Hansjuerg Alder; Ramana V Davuluri; Laura Z Rassenti; Massimo Negrini; Tatsuya Nakamura; Dino Amadori; Neil E Kay; Kanti R Rai; Michael J Keating; Thomas J Kipps; George A Calin; Carlo M Croce
Journal:  JAMA       Date:  2011-01-05       Impact factor: 56.272

4.  Age at diagnosis and the utility of prognostic testing in patients with chronic lymphocytic leukemia.

Authors:  Tait D Shanafelt; Kari G Rabe; Neil E Kay; Clive S Zent; Diane F Jelinek; Megan S Reinalda; Susan M Schwager; Debbie A Bowen; Susan L Slager; Curtis A Hanson; Timothy G Call
Journal:  Cancer       Date:  2010-10-15       Impact factor: 6.860

5.  Incidence of chronic lymphocytic leukemia and high-count monoclonal B-cell lymphocytosis using the 2008 guidelines.

Authors:  Timothy G Call; Aaron D Norman; Curtis A Hanson; Sara J Achenbach; Neil E Kay; Clive S Zent; Wei Ding; James R Cerhan; Kari G Rabe; Celine M Vachon; Emily J Hallberg; Tait D Shanafelt; Susan L Slager
Journal:  Cancer       Date:  2014-04-07       Impact factor: 6.860

Review 6.  Exploring Big Data in Hematological Malignancies: Challenges and Opportunities.

Authors:  Gustavo F Westin; Ajoy L Dias; Ronald S Go
Journal:  Curr Hematol Malig Rep       Date:  2016-08       Impact factor: 3.952

7.  Prognostic importance of T and NK-cells in a consecutive series of newly diagnosed patients with chronic lymphocytic leukaemia.

Authors:  Shanique Palmer; Curtis A Hanson; Clive S Zent; Luis F Porrata; Betsy Laplant; Susan M Geyer; Svetomir N Markovic; Timothy G Call; Deborah A Bowen; Diane F Jelinek; Neil E Kay; Tait D Shanafelt
Journal:  Br J Haematol       Date:  2008-04-01       Impact factor: 6.998

8.  Validation of a new prognostic index for patients with chronic lymphocytic leukemia.

Authors:  Tait D Shanafelt; Greg Jenkins; Timothy G Call; Clive S Zent; Susan Slager; Deborah A Bowen; Susan Schwager; Curtis A Hanson; Diane F Jelinek; Neil E Kay
Journal:  Cancer       Date:  2009-01-15       Impact factor: 6.860

9.  Medical history, lifestyle, family history, and occupational risk factors for chronic lymphocytic leukemia/small lymphocytic lymphoma: the InterLymph Non-Hodgkin Lymphoma Subtypes Project.

Authors:  Susan L Slager; Yolanda Benavente; Aaron Blair; Roel Vermeulen; James R Cerhan; Adele Seniori Costantini; Alain Monnereau; Alexandra Nieters; Jacqueline Clavel; Timothy G Call; Marc Maynadié; Qing Lan; Christina A Clarke; Tracy Lightfoot; Aaron D Norman; Joshua N Sampson; Delphine Casabonne; Pierluigi Cocco; Silvia de Sanjosé
Journal:  J Natl Cancer Inst Monogr       Date:  2014-08

10.  Chronic lymphocytic leukemia and myeloproliferative neoplasms concurrently diagnosed: clinical and biological characteristics.

Authors:  Gabriele Todisco; Taghi Manshouri; Srdan Verstovsek; Lucia Masarova; Sherry A Pierce; Michael J Keating; Zeev Estrov
Journal:  Leuk Lymphoma       Date:  2015-10-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.